Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones

Reference

• AMENT, P. W., JAMSHED, N. and HORNE, J. P., 2002, Linezolid: its role in the treatment of Gram-positive, drug-resistant bacterial infections. American Family Physician, 65, 663–670.
   PubMed Web of Science ®Google Scholar
• AVILES, P., PATEMAN, A., SAN ROMAN, R., GUILLEN, M. J., GOMEZ DE LASHERA, F. and GARGALLO-VIOLA, D., 2001, Animal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration. Antimicrobial Agents and Chemotherapy, 45, 2787–2792.
   Google Scholar
• BOUZA, E. and MUNOZ, P., 2001, Linezolid: pharmacokinetic characteristics and clinical studies. Clinical Microbial Infections, 7, 75–82.
   PubMed Web of Science ®Google Scholar
• BOXENBAUM, H., 1984, Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metabolism Reviews, 15, 1071–1112.
   PubMed Web of Science ®Google Scholar
• BRIER, M. E., STALKER, D. J., ARONOFF, G. R., BATTS, D. H., RYAN, K. K., O'GRADY, M., HOPKINS, N. K. and JUNGBLUTH, G. L., 2003, Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrobial Agents and Chemotherapy, 47, 2775–2780.
   Google Scholar
• FORD, C. W., ZURENKO, G. E. and BARBACHYN, M. R., 2001, The discovery of linezolid, the first oxazolidinone antibacterial agent. Current Drug Targets in Infectious Disorders, 1, 181–199.
   PubMedGoogle Scholar
• HENDERSHOT, P. E., ANTAL, E. J., WELSHMAN, I. R., BATTS, D. H. and HOPKINS, N. K., 2001, Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HC1, phenylpropanol-amine HC1, and dextromethorpan HBr. Journal of Clinical Pharmacology, 41, 563–572.
   PubMed Web of Science ®Google Scholar
• KHOR, S. P., MCCARTHY, K., Du PONT, M., MURRAY, K. and TIMONY, G., 2000, Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. Journal of Pharmacology and Experimental Therapeutics, 293, 618–624.
   PubMed Web of Science ®Google Scholar
• MACGOWAN, A. P., 2003, Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. Journal of Antimicrobial Chemotherapy, 51, 17–25.
   Google Scholar
• MAHMOOD, I., 2001a, Interspecies scaling of maximum tolerated dose of anticancer drugs: relevance to starting dose for phase I clinical trials. American Journal of Therapeutics, 8, 109–116.
   PubMedGoogle Scholar
• MAHMOOD, I., 2001b, Interspecies scaling: is a priori knowledge of cytochrome p450 isozymes involved in drug metabolism helpful in prediction of clearance in humans from animal data. Drug Metabolism and Drug Interaction, 18, 135–147.
   PubMedGoogle Scholar
• MAHMOOD, I., 2002, Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metabolism and Drug Interaction, 19, 49–64.
   PubMedGoogle Scholar
• MOELLERING, R. C., 2003, Linezolid: the first oxazolidinone antimicrobial. Annals of Internal Medicine, 138, 144.
   Google Scholar
• PERRY, C. M. and JARvis, B., 2001, Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs, 61, 525–551.
   PubMed Web of Science ®Google Scholar
• PHARMACIA AND UPJOHN, 2000, ZyvoxTM (linezolid) brochure for the anti-infective drug products advisory committee meeting (available at: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/ 3597b1ba.pdf).
   Google Scholar
• SHIN, B. S., Km, D. H., CHO, C. Y., PARK, S. K., CHUNG, S. G., CHO, E. H., LEE, S. H., Joo, J. H., KWON, H. S., LEE, K. C. and Yoo, S. D., 2003, Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, species-invariant time methods. Biopharmaceutics and Drug Disposition, 24, 191–197.
   PubMed Web of Science ®Google Scholar
• SISSON, T. L., JUNGBLUTH, G. L. and HOPKINS, N. K., 2002, Age and sex effects on the pharmacokinetics of linezolid. European Journal of Clinical Pharmacology, 57,793–797
   PubMed Web of Science ®Google Scholar
• SLATTER, J. G., ADAMS, L. A, BUSH, E. C, CHIBA, K, DALEY-YATES, P. T., FEENSTRA, K. L., KOIKE, S., OZAWA, N., PENG, G. W., SAMS, J. P., SCHUETTE, M. R. and YAMAZAKI, S., 2002, Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica, 32, 907–924.
   Google Scholar
• SLATTER, J. G., STALKER, D. J., FEENSTRA, K. L., WELSHMAN, I. R., BRUSS, J. B., SAMS, J. P., JOHNSON, M. G., SANDERS, P. E, HAUER, M. J., FAGERNESS, P. E., STRYD, R. P., PENG, G. W. and SHOBE, E. M., 2001, Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C] linezolid to healthy human subjects. Drug Metabolism and Disposition, 29, 1136–1145.
   PubMed Web of Science ®Google Scholar
• STALKER, D. and JUNGBLUTH, G., 2003, Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clinical Pharmacokinetics, 42, 1129–1140.
   PubMed Web of Science ®Google Scholar
• STALKER, D. J., JUNGBLUTH, G. L., HOPKINS, N. K. and BATTS, D. H., 2003, Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. Journal of Antimicrobial and Chemotherapy, 51, 1239–1246.
   PubMed Web of Science ®Google Scholar
• SUKBUNTHERNG, J., CROPP, G., HANNAH, A., WAGNER, G. S., SHAWVER, L. K. and ANTONIAN, L., 2001, Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, 5U5416. Journal of Pharmacy and Pharmacology, 53, 1629–1636.
   PubMed Web of Science ®Google Scholar
• WARD, K. W., PROKSCH, J. W., GORYCKI, P. D., Yu, C. P., Ho, M. Y., BUSH, B. D., LEVY, M. and SMITH, B. R., 2002, SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: in vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man. Xenobiotica, 32, 235–250.
   PubMed Web of Science ®Google Scholar
• WELSHMAN, I. R., SISSON, T. A., JUNGBLUTH, G. L., STALKER, D. J. and HOPKINS, N. K., 2001, Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharnzaceutics and Drug Disposition, 22, 91–97.
   PubMed Web of Science ®Google Scholar
• WIENKERS, L. C., WYNDALDA, M. A., FEENSTRA, K. L., GAO, P. and SLATER, J. G., 1999, In vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586. In Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
   Google Scholar
• WYNALDA, M. A., MICHAEL, J. H. and LARRY, C. W., 2000, Oxidation of novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metabolism Disposition, 20, 1014–1017.
   Google Scholar